Effect of Somatostatin on TSH levels in non-toxic sporadic goiter.
Somatostatin (SS-14; growth hormone-release inhibiting hormone) was infused into eight patients with non-toxic sporadic goiter and into eleven normal control subjects. Each patient was given 150 microgram(s) of somatostatin as an intravenous bolus and 350 microgram(s) by infusion over a period of 60 minutes. Somatostatin did not lower the basal TSH levels as compared to the pre-infusion levels in this type of goiter, but produced a decrease in the TSH response to TRH during and after the infusion.
Varea
J
J
Endocrine Service, Carlos Andrade Marin Hospital, Ecuadorian Social Security Institute, Quito.
Paredes
M
M
Garces
G
G
Ochoa
C
C
Avila
C
C
Coloma
M J
MJ
Briones
R
R
Comaru-Schally
A M
AM
Schally
A V
AV
D000328:Adult; D006042:Goiter / Q000097:blood*; D006801:Humans; D007262:Infusions, Intravenous; D007700:Kinetics; D008875:Middle Aged; D012016:Reference Values; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology*; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone
D013004:Somatostatin; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin